Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Okyanos Celebrates 1-Year Anniversary Milestones
  • USA - English


News provided by

Okyanos

Nov 04, 2015, 09:00 ET

Share this article

Share toX

Share this article

Share toX

Cell Therapy Cath Lab
Cell Therapy Cath Lab
Youtube
Youtube

Freeport, Grand Bahama (PRWEB) November 04, 2015 -- Okyanos, the leader in cell therapy for chronic disease, celebrated its first anniversary in October. Reflecting on a year of improving patients’ quality of life, a number of milestones were achieved.

Our ability to help patients suffering from chronic, degenerative diseases is a point of pride for the team. - CEO Okyanos Mathew Feshbach

Post this

“Okyanos was founded in August, 2011 with the goal to provide patients with the most advanced technology for separating their own stem cells from adipose (fat) tissue, combined with imaging, delivery and monitoring technology to ensure that Okyanos’ patients had the highest standard of safety and care,” says Okyanos co-founder and CEO, Matthew Feshbach. "Our ability to help patients suffering from chronic, degenerative diseases is a point of pride for the team.”

Okyanos began treating patients in October, 2014 after becoming the first fully licensed cell therapy provider in The Bahamas, as granted by the country’s National Stem Cell Ethics Committee (NSEC).

Throughout the year, Okyanos patients have benefited from use of the most advanced technology available for cell processing—the internationally-approved Celution 800 IV system, which provides the highest yield of therapeutic cells and has been approved for safe delivery into the vascular system including the heart. In addition, Okyanos technology includes a Philips bi-plane cath lab and Perkins imaging system, providing a 3-D image of the heart alongside use of the C-cath delivery catheter. These combined technologies provide no-option congestive heart failure patients with the highest standard of safety for the delivery of adipose-derived stem and regenerative cells (ADRCs) into the heart muscle for the repair of damage from prior heart attacks, restoration of heart function and an improved quality of life.

“Okyanos is the first true cell therapy center of excellence in the world,” said Prof. Dr. Eric Duckers, Chairman of the Okyanos Medical Advisory Council and a recognized leader in regenerative medicine research. “This purpose-built facility is ideal for patients with autoimmune, orthopedic, cardiovascular and neurological conditions to safely receive the highest possible therapeutic dose of ADRCs due to their technological investments.”

Okyanos has also established leadership in the the cell therapy field by demonstrating the ability to treat patients with complex conditions, in many cases involving more than one degenerative disease (co-morbidities).

Paul, a leading IVF doctor from the UK and an Okyanos patient, recently shared the details of how nearly a decade ago, crippling neuropathy robbed him of his quality of life. “Eventually the pain was like a red-hot poker jammed up my heels. But the worst thing really was the loss of mobility,” says Dr. Paul. “I couldn’t stand for more than 2-3 minutes without extreme pain. I was virtually reduced to a wheelchair.”

After years of trying every imaginable treatment, Dr. Paul’s medical science background and strong desire for long-term relief led him to Okyanos, where he was treated in April, 2015.

“Gone is the red-hot poker pain. Also, my feet—diabetics commonly get claw toes where the toes are not straight due to blood flow diminishing, as well as ulcers, skin conditions, and sweating. All those things have disappeared,” he shares. “After almost half a century in medicine, I’ve seen a lot of operations all over the world, and Okyanos is absolutely amazing. It’s not just the treatment and the equipment but the way people treat you.”

Okyanos has also begun to contribute to the advancement of cell therapy research, having just recently completed the initial stages of a privately-funded study of patients with progressive multiple sclerosis, many of whom are now in post-treatment follow-up.

Looking to the future of Okyanos Cell Therapy, co-founder and CEO Matthew Feshbach shares a piece of the healthcare company’s vision for 2016:

“Okyanos cell therapy has been developed on a foundation of vast scientific and clinical research, which is an evolving body of knowledge,” says Feshbach. “We remain active members of the scientific community and adopt only technologies and protocols into Okyanos treatment which align with our mission, which is to help patients with chronic, degenerative conditions to return to a more normal life.”

Just 55 miles from US shore, Okyanos Cell Therapy is available to patients suffering with the daily limitations of heart disease, neuropathy, diabetes, multiple sclerosis, arthritis, orthopedic problems and other chronic, degenerative conditions. This innovative procedure is premised on the healing power of adult stem cells isolated from the patient’s body fat which have the ability to decrease inflammation, repair damaged tissue and stimulate new blood vessel growth.

Patients can contact Okyanos to learn more and request a complimentary consultation with one of our doctors by visiting http://www.okyanos.com or by calling 1-855-659-2667.

About Okyanos: (Oh – key – AH – nos)
Based in Freeport, Grand Bahama, Okyanos helps patients with chronic, degenerative conditions get back to a more normal life with cell therapy. This innovative treatment utilizes a unique blend of multipotent stem and regenerative cells derived from patients’ own adipose (fat) tissue which have been established in research to possess multiple mechanisms that address inflammation, poor blood flow, neurodegeneration, destructive immune response and tissue degeneration. Okyanos is fully licensed under the Bahamas Stem Cell Therapy and Research Act and has been specially built to U.S. surgical center standards. The literary name Okyanos, the Greek god of the river Okyanos, symbolizes restoration of blood flow.

Corina Froese, Okyanos, http://www.okyanos.com, +1 818-398-0179, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.